CABINET OFFICE, GOVERMENT OF JAPAN - 19 August 2011

Japan's 4th Science and Technology Basic Plan which Guides the Country's S&T Policy following 5 Years is Approved by the Cabinet. It Focuses Pro-Innovation and Emphasizes "Life Innovation" as a Pillar of Growth along with "Green Innovation".
http://www8.cao.go.jp/cstp/english/policy/reports.html

 Ministry of Health, Labour and Welfare - July 2011

MHLW has selected 5 Core Centers for First-in-Human and Exploratory Studies to create Innovative Medicines and Medical Devices originated from Japan's Academic Outcomes. Budgeted \ 3.3 B/year, the Centers will be granted for 5 years.
http://www.mhlw.go.jp/stf/houdou/2r9852000001jym4.html(in Japanese)

 Partner Tetsuya Mishima Interviewed - November 2009

http://www.venturevaluation.com/vv_web/files/WaterveinPartners.pdf

　SCRIP - 29 December 2011 

Second pharma deal further validates Interprotein's discovery technology
http://www.scripintelligence.com/researchdevelopment/Second-pharma-deal-further-validates-Interproteins-discovery-technology-325263

　SCRIP - 22 November 2011 

Ajinomoto investigates protein-protein inhibitors in discovery alliance with Interprotein
http:www.scripintelligence.com/researchdevelopment/Ajinomoto-investigates-protein-protein-inhibitors-in-discovery-alliance-with-Interprotein-323908

　PLoS ONE - 17 August 2011 

A Kinopharma's Kinase Inhibitor Proved to have Anti-virus Efficacy in Dengue Viruses.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0023246

　Interviewed by Venture Valuation AG - NOVEMBER 2009 

Interprotein Corporation CEO is interviewed by Venture Valuation, a Swiss independent assessment and valuation of technology-driven companies in growth industries.
http://www.venturevaluation.com/vv_web/files/interprotein.pdf

　Interviewed by Venture Valuation AG - AUGUST 2009 

Anaeropharma CEO is interviewed by Venture Valuation, a Swiss independent assessment and valuation of technology-driven companies in growth industries.
http://www.venturevaluation.com/vv_web/files/Anaeropharma_Science.pdf

　The 9th World Congress on Inflammation - July 2009 

Dr. Takao Matsuzaki, Chief Drug Designer Interprotein Corporation, Speaks On-going Research Outcomes in DeNovo Drug Design for Protein-protein Interaction Targets.
http://www2.convention.co.jp/wci2009/pro/wci_program.pdf

ASIA PRIVATE EQUITY REVIEW - FEBRUARY 2004